697 related articles for article (PubMed ID: 24622842)
1. Driver mutations of cancer epigenomes.
Roy DM; Walsh LA; Chan TA
Protein Cell; 2014 Apr; 5(4):265-96. PubMed ID: 24622842
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
3. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract][Full Text] [Related]
4. Histone profiles in cancer.
Riedel SS; Neff T; Bernt KM
Pharmacol Ther; 2015 Oct; 154():87-109. PubMed ID: 26210403
[TBL] [Abstract][Full Text] [Related]
5. EZH2, an epigenetic driver of prostate cancer.
Yang YA; Yu J
Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
7. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
8. Somatic alterations and dysregulation of epigenetic modifiers in cancers.
Aumann S; Abdel-Wahab O
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):24-34. PubMed ID: 25111821
[TBL] [Abstract][Full Text] [Related]
9. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
10. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
11. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
12. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer.
Plass C; Pfister SM; Lindroth AM; Bogatyrova O; Claus R; Lichter P
Nat Rev Genet; 2013 Nov; 14(11):765-80. PubMed ID: 24105274
[TBL] [Abstract][Full Text] [Related]
13. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
14. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
Silverman BR; Shi J
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
[TBL] [Abstract][Full Text] [Related]
17. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
18. Maternal Exposure to High-Fat Diet Induces Long-Term Derepressive Chromatin Marks in the Heart.
Blin G; Liand M; Mauduit C; Chehade H; Benahmed M; Simeoni U; Siddeek B
Nutrients; 2020 Jan; 12(1):. PubMed ID: 31936461
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
20. Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors.
Yasuda H; Soejima K; Watanabe H; Kawada I; Nakachi I; Yoda S; Nakayama S; Satomi R; Ikemura S; Terai H; Sato T; Suzuki S; Matsuzaki Y; Naoki K; Ishizaka A
Int J Oncol; 2010 Dec; 37(6):1537-46. PubMed ID: 21042723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
